These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7811027)

  • 41. Metronidazole and spiramycin in abscesses caused by Bacteroides spp. and Staphylococcus aureus in mice.
    Brook I
    J Antimicrob Chemother; 1987 Nov; 20(5):713-8. PubMed ID: 3429373
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp.
    Nasu M; Maskell JP; Williams RJ; Williams JD
    Antimicrob Agents Chemother; 1981 Oct; 20(4):433-6. PubMed ID: 6282191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inducible metronidazole resistance in nim-positive and nim-negative bacteroides fragilis group strains after several passages metronidazole containing columbia agar plates.
    Schaumann R; Petzold S; Fille M; Rodloff AC
    Infection; 2005 Oct; 33(5-6):368-72. PubMed ID: 16258869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reciprocal antimicrobial synergism between Escherichia coli and Bacteroides fragilis in the presence of metronidazole.
    Soriano F; Ponte MC; Gaspar MC
    J Clin Pathol; 1982 Oct; 35(10):1150-2. PubMed ID: 6752209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
    Sprandel KA; Drusano GL; Hecht DW; Rotschafer JC; Danziger LH; Rodvold KA
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study.
    Bandoh K; Ueno K; Watanabe K; Kato N
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S382-6. PubMed ID: 8324152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
    Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
    Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity.
    Gupta AK; Kohli Y
    Br J Dermatol; 2003 Aug; 149(2):296-305. PubMed ID: 12932235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Antibacterial and bactericidal activity of tinidazole against anaerobic bacteria comparing with metronidazole (author's transl)].
    Ninomiya K; Kobata S; Imamura H; Mochizuki I; Watanabe K
    Jpn J Antibiot; 1976 Mar; 29(3):325-31. PubMed ID: 1271586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metronidazole and spiramycin therapy of mixed Bacteroides spp. and Neisseria gonorrhoeae infection in mice.
    Brook I
    Chemotherapy; 1989; 35(2):105-12. PubMed ID: 2503299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
    Spangler SK; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():23-7. PubMed ID: 9222066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. German multicentre study on the in vitro susceptibility of Bacteroides species. The German Bacteroides Study Group.
    Rodloff AC; Werner H; Kresken M; Jansen A
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1074-80. PubMed ID: 1295762
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [In vitro effect of piperacillin, amoxicillin, cefoxitin and metronidazole against obligate anaerobic bacteria].
    Derriennic M; Reynaud A; Launay C; Courtieu AL
    Presse Med; 1986 Dec; 15(46):2279-81. PubMed ID: 2949268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative antimicrobial activity of metronidazole and the hydroxy metabolite against Gardnerella vaginalis.
    Ralph ED
    Scand J Infect Dis Suppl; 1983; 40():115-20. PubMed ID: 6607518
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.
    Betriu C; Cabronero C; Gomez M; Picazo JJ
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three independent yearly analyses of the spectrum and potency of metronidazole: a multicenter study of 1,108 contemporary anaerobic clinical isolates.
    Erwin ME; Fix AM; Jones RN
    Diagn Microbiol Infect Dis; 2001 Feb; 39(2):129-32. PubMed ID: 11248527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
    Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K; Ueno K; Kato N; Muto Y; Bandoh K; Tanaka Y; Jotwani R; Goto M; Shimada K; Shimizu K
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL
    Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergistic effects between amoxicillin, metronidazole, and the hydroxymetabolite of metronidazole against Actinobacillus actinomycetemcomitans.
    Pavicić MJ; van Winkelhoff AJ; de Graaff J
    Antimicrob Agents Chemother; 1991 May; 35(5):961-6. PubMed ID: 1854177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.